{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04982354",
            "orgStudyIdInfo": {
                "id": "2019-KOE-003"
            },
            "organization": {
                "fullName": "Baptist Health South Florida",
                "class": "OTHER"
            },
            "briefTitle": "Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia",
            "officialTitle": "A Pilot Study of Daunorubicin-cytarabine Liposome (CPX-351) Plus FLT3-inhibitor (Midostaurin) as Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia Followed by Consolidation With a CD34+-Selected Allograft",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "induction-therapy-for-patients-with-mutated-acute-myeloid-leukemia"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-04",
            "overallStatus": "RECRUITING",
            "startDateStruct": {
                "date": "2022-07-05",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2031-08-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2032-08-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-07-13",
            "studyFirstSubmitQcDate": "2021-07-28",
            "studyFirstPostDateStruct": {
                "date": "2021-07-29",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-04-08",
            "lastUpdatePostDateStruct": {
                "date": "2024-04-09",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR_INVESTIGATOR",
                "investigatorFullName": "Guenther Koehne",
                "investigatorTitle": "Deputy Director and Chief of Blood and Marrow Transplant, Hematologic Oncology and Benign Hematology",
                "investigatorAffiliation": "Baptist Health South Florida"
            },
            "leadSponsor": {
                "name": "Guenther Koehne",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Jazz Pharmaceuticals",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "This is a pilot study designed to identify the effect of daunorubicin-cytarabine liposome (CPX-351) in combination with a FLT3-inhibitor (midostaurin) as induction and consolidation therapy for patients with high-risk FLT3 mutated acute myeloid leukemia (AML) and subsequent CD34+-selected allogeneic stem cell transplant from HLA compatible related or unrelated donors."
        },
        "conditionsModule": {
            "conditions": [
                "Acute Myeloid Leukemia"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 20,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Investigational Treatment",
                    "type": "EXPERIMENTAL",
                    "description": "Daunorubicin-cytarabine liposome (CPX-351) Plus FLT3-inhibitor (Midostaurin) Induction Therapy followed by Busulfan/Melphalan/Fludarabine Conditioning therapy and CD34+-selected allografts.",
                    "interventionNames": [
                        "Drug: CPX-351",
                        "Drug: Midostaurin",
                        "Drug: Busulfan",
                        "Drug: Melphalan",
                        "Drug: Fludarabine",
                        "Biological: CD34+ selected allogeneic stem cell transplant from an HLA-compatible donor"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "CPX-351",
                    "description": "For this trial, patients will be treated with CPX-351 100 (daunorubicin 44 mg/m2 and cytarabine 100 mg/m2) for 3 doses on days 1, 3 and 5 of one and on days 1 + 3 of a second cycle of induction therapy, depending on response obtained following the first induction. Thereafter, up to 2 cycles of consolidation therapy of 2 doses on days 1 and 3 of daunorubicin 29 mg/m2 and cytarabine 65 mg/m2 will be administered to the patients.",
                    "armGroupLabels": [
                        "Investigational Treatment"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Midostaurin",
                    "description": "The FLT3 directed inhibitor, midostaurin, will be given at a dose of 50mg twice daily, starting on day 8 through day 21 of each cycle of CPX-351 until admission for allogeneic stem cell transplant.",
                    "armGroupLabels": [
                        "Investigational Treatment"
                    ],
                    "otherNames": [
                        "Rydapt"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Busulfan",
                    "description": "0.8 mg/kg/dose every six hours x 12 doses administered intravenously",
                    "armGroupLabels": [
                        "Investigational Treatment"
                    ],
                    "otherNames": [
                        "Myleran"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Melphalan",
                    "description": "70 mg/m2/day x 2 doses administered intravenously",
                    "armGroupLabels": [
                        "Investigational Treatment"
                    ],
                    "otherNames": [
                        "Alkeran"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Fludarabine",
                    "description": "25 mg/m2/day x 5 doses administered intravenously",
                    "armGroupLabels": [
                        "Investigational Treatment"
                    ],
                    "otherNames": [
                        "Fludara"
                    ]
                },
                {
                    "type": "BIOLOGICAL",
                    "name": "CD34+ selected allogeneic stem cell transplant from an HLA-compatible donor",
                    "description": "Allogeneic stem cell transplant infused intravenously",
                    "armGroupLabels": [
                        "Investigational Treatment"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Change in the complete remission rate",
                    "description": "Assess the complete remission rate following induction therapy with CPX-351 plus midostaurin when administered to patients",
                    "timeFrame": "3, 6, 12 and 24 months"
                },
                {
                    "measure": "Change in Progression Free Survival (PFS)",
                    "description": "to determine the PFS of these patients following allo SCT. To estimate PFS the Kaplan-Meier method will be used.",
                    "timeFrame": "3, 6, 12 and 24 months"
                },
                {
                    "measure": "Change in Overall Survival (OS)",
                    "description": "to determine the OS of these patients following allo SCT. To estimate OS the Kaplan-Meier method will be used.",
                    "timeFrame": "3, 6, 12 and 24 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Change in the rate of Minimal Residual Disease (MRD) negativity",
                    "description": "Ascertain the rate of MRD negativity by next generation sequencing at sequential time post following induction treatment at complete remission prior to allo Stem Cell Transplantation (SCT)",
                    "timeFrame": "3, 6, 12 and 24 months"
                },
                {
                    "measure": "Correlation of Minimal Residual Disease (MRD)",
                    "description": "Correlation of duration of MRD negative status with duration of complete remission of these patients will be assessed using Spearman's correlation with reported p value.",
                    "timeFrame": "3, 6, 12 and 24 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients must have a Karnofsky (adult) Performance Status of at least 70%.\n* Patients must have adequate organ function\n\nExclusion Criteria:\n\n* Female patients who are pregnant or breast-feeding\n* Active viral, bacterial or fungal infection\n* Patient seropositive for Human Immunodeficiency Virus (HIV-I /II); Human T-Cell Lymphotrophic Virus (HTLV -I /II)\n* Presence of leukemia in the Central Nervous System (CNS).",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "74 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Guenther Koehne, MD, PhD",
                    "role": "CONTACT",
                    "phone": "786-596-2000",
                    "email": "GuentherK@Baptisthealth.net"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Guenther Koehne, MD. PhD",
                    "affiliation": "Miami Cancer Institute at Baptist Health of South Florida",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Miami Cancer Institute at Baptist Health of South Florida",
                    "status": "RECRUITING",
                    "city": "Miami",
                    "state": "Florida",
                    "zip": "33176",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Guenther Koehne, MD, PhD",
                            "role": "CONTACT",
                            "phone": "786-596-2000",
                            "email": "GuentherK@Baptisthealth.net"
                        },
                        {
                            "name": "Guenther Koehne, MD, PhD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 25.77427,
                        "lon": -80.19366
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Miami Cancer Institute Website",
                    "url": "http://baptisthealth.net/cancer-care/home"
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000007938",
                    "term": "Leukemia"
                },
                {
                    "id": "D000007951",
                    "term": "Leukemia, Myeloid"
                },
                {
                    "id": "D000015470",
                    "term": "Leukemia, Myeloid, Acute"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M10945",
                    "name": "Leukemia",
                    "asFound": "Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10955",
                    "name": "Leukemia, Myeloid",
                    "asFound": "Myeloid Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M18127",
                    "name": "Leukemia, Myeloid, Acute",
                    "asFound": "Acute Myeloid Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T3995",
                    "name": "Myeloid Leukemia",
                    "asFound": "Myeloid Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T182",
                    "name": "Acute Myeloid Leukemia",
                    "asFound": "Acute Myeloid Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T188",
                    "name": "Acute Non Lymphoblastic Leukemia",
                    "asFound": "Acute Myeloid Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T170",
                    "name": "Acute Graft Versus Host Disease",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000024352",
                    "term": "Fludarabine"
                },
                {
                    "id": "D000008558",
                    "term": "Melphalan"
                },
                {
                    "id": "D000002066",
                    "term": "Busulfan"
                },
                {
                    "id": "C000059539",
                    "term": "Midostaurin"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000007166",
                    "term": "Immunosuppressive Agents"
                },
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018906",
                    "term": "Antineoplastic Agents, Alkylating"
                },
                {
                    "id": "D000000477",
                    "term": "Alkylating Agents"
                },
                {
                    "id": "D000019653",
                    "term": "Myeloablative Agonists"
                },
                {
                    "id": "D000047428",
                    "term": "Protein Kinase Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M11541",
                    "name": "Melphalan",
                    "asFound": "Controlled Study",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6766",
                    "name": "Cytarabine",
                    "relevance": "LOW"
                },
                {
                    "id": "M6832",
                    "name": "Daunorubicin",
                    "relevance": "LOW"
                },
                {
                    "id": "M5336",
                    "name": "Busulfan",
                    "asFound": "Anesthetic",
                    "relevance": "HIGH"
                },
                {
                    "id": "M283230",
                    "name": "Fludarabine",
                    "asFound": "Rate",
                    "relevance": "HIGH"
                },
                {
                    "id": "M225513",
                    "name": "Fludarabine phosphate",
                    "relevance": "LOW"
                },
                {
                    "id": "M353083",
                    "name": "Midostaurin",
                    "asFound": "Bronchoalveolar",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10212",
                    "name": "Immunosuppressive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20942",
                    "name": "Antineoplastic Agents, Alkylating",
                    "relevance": "LOW"
                },
                {
                    "id": "M3820",
                    "name": "Alkylating Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M25820",
                    "name": "Protein Kinase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                }
            ]
        }
    },
    "hasResults": false
}